Impax Laboratories Inc (IPXL)

23.79
0.08 0.34
NASDAQ : Health Care
Prev Close 23.87
Open 23.99
Day Low/High 23.65 / 25.25
52 Wk Low/High 20.97 / 46.10
Volume 2.07M
Avg Volume 858.60K
Exchange NASDAQ
Shares Outstanding 73.86M
Market Cap 1.77B
EPS 0.60
P/E Ratio 48.02
Div & Yield N.A. (N.A)

Latest News

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.

Short Interest Expands By 12.8% For IPXL

Short Interest Expands By 12.8% For IPXL

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 709,063 share increase in total short interest for Impax Laboratories Inc , to 6,260,150, an increase of 12.77% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Impax Names Douglas S. Boothe President Of Generics Division

Impax Names Douglas S. Boothe President Of Generics Division

-- Experienced Executive Added to Advance Robust Generic Portfolio --

Teva Inches Closer to Completion of Allergan Generics Deal

Teva Inches Closer to Completion of Allergan Generics Deal

Australia's Mayne will shell out $652 million for a basket of generics products from Teva as the latter works to complete its pending Allergan generics purchase.

Impax Laboratories (IPXL) Marked As A Dead Cat Bounce Stock

Impax Laboratories (IPXL) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a "dead cat bounce" (down big yesterday but up big today) candidate

What Exactly Did Allergan and Teva Sell to Impax?

What Exactly Did Allergan and Teva Sell to Impax?

The deal helps the Israeli drug giant comply with required antitrust divestitures connected to completion of its $40.5 billion acquisition of the generics business of Allergan.

Impax (IPXL) Stock Tumbles on Teva, Allergan Generic Drug Deal

Impax (IPXL) Stock Tumbles on Teva, Allergan Generic Drug Deal

Impax Laboratories (IPXL) stock is plunging after the company agreed to buy a portfolio of generic drugs from Teva Pharmaceuticals (TEVA) and Allergan (AGN) for $586 million.

Impax Laboratories (IPXL) Highlighted As Weak On High Volume

Impax Laboratories (IPXL) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a weak on high relative volume candidate

Impax Signs Definitive Agreements To Acquire Generic Products

Impax Signs Definitive Agreements To Acquire Generic Products

- Transaction Expected to Enhance Earnings Growth Potential -

Impax Announces Availability Of EMVERM™ (mebendazole) Chewable Tablets, 100 Mg

Impax Announces Availability Of EMVERM™ (mebendazole) Chewable Tablets, 100 Mg

EMVERM Provides a New Option for Patients with Pinworm, Whipworm, Roundworm and Hookworm in Single or Mixed Infections

4 More Good 'Chicken Shorts'

These overpriced stocks lend themselves to puts or put spreads.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CAG, CCBG, CREE, ESRT, MLNX, MPX, PDCO, TMUS, VSAT, WMT Downgrades: BKU, FFIN, INSY, IPXL, LM, MGLN, MRC, THC Initiations: ONDK, VLRS Read on to get TheStreet Quant Ratings' detailed report:

Impax Laboratories (IPXL) Stock Drops Despite Earnings Beat

Impax Laboratories (IPXL) Stock Drops Despite Earnings Beat

Impax Laboratories (IPXL) stock is declining on Monday after posting its 2015 fourth quarter results before today’s opening bell.

Impax Receives Approval Of EMVERM™ (mebendazole) Chewable Tablets, 100 Mg

Impax Receives Approval Of EMVERM™ (mebendazole) Chewable Tablets, 100 Mg

EMVERM Provides a New Option for Patients with Pinworm, Whipworm, Roundworm and Hookworm in Single or Mixed Infections

Impax Laboratories (IPXL) Strong on High Relative Volume Today

Impax Laboratories (IPXL) Strong on High Relative Volume Today

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a strong on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AZN, HZO, IPXL, SCAI, YY Downgrades: ADUS, CS, CSTE, EEI, FDUS, FNV, MDU, MSON, PEGI, TRC Initiations: HYH Read on to get TheStreet Quant Ratings' detailed report: